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ABSTRACT 
Objective: To explore a possible significance of the presence of anti-ganglioside and anti-sulfatide anti- bodies in sera of adult 
patients with celiac disease (CD) in different clinical scenario. 
Methods: We selected 22 adult patients with newly diagnosed CD and 20 age–sex matched non-CD controls. Patients’ serum was 
tested – before and after at least 6 months on a gluten-free diet (GFD) –    for anti-GM1, GM2, GM3, GD1a, GD1b, GD3, GT1a, GT1b, 
GQ1b and sulfatide IgM, IgG and IgA auto- antibodies, by means of a dot blot technique and enzyme-linked immunosorbent assay 
(ELISA). 
Results: We found the presence of auto-antibodies in untreated  patients. In  particular,  anti-sulfatide  IgG antibodies were present in 
8 (36%) patients independently of the presence of  neurological  symp-  toms. Anti-sulfatide IgA antibodies were present in 3 (19%) 
patients. During GFD, anti-sulfatide IgG dis- appeared in all the patients, whereas IgA were observed in 2 patients. Anti-sulfatide, anti-
GM1 and anti-GM2 IgM antibodies were also observed in 2  patients  on  a  GFD.  All  the  other  auto-antibodies  were absent and no 
demographic or clinical parameters were associated. Non-CD controls did  not pre-  sent  any auto-antibody. 
Conclusions: We found anti-sulfatide IgG antibodies in CD patients on a gluten-containing diet. Anti-sulfatide IgA antibodies 
persisted during GFD together with the occurrence of other IgM auto- antibodies. These data suggest a possible link between 
gluten and IgG auto-antibodies. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Celiac disease (CD) is a common autoimmune enteropathy 
triggered by the ingestion of gluten proteins in genetically 
susceptible individuals carrying the HLA type  II  DQ2  and/or  
DQ8 haplotypes. Although the small bowel is the main tar-  
geted  organ  and  localization  of  the  inflammatory  damage,  
CD is considered a systemic disorder as different tissues and 
organs, including the central and peripheral nervous systems,  
are involved. Approximately, 10% of CD patients show neuro- 
logical symptoms,[1] in particular cerebellar ataxia, peripheral 
neuropathy  (PN)  and epilepsy.[2–4] 
The pathogenesis of  the  neurological  complications  in  CD  
is still unclear; vitamin deficiency could be considered  in case   
of malabsorption and  extensive  small-bowel  atrophy.  
However, this mechanism does not justify all the cases, espe- 
cially those with normal  levels  of  vitamins  and  without  a  
clear malabsorptive syndrome. It could be supposed that sys- 
temic inflammation and the consequent increase in cytokines 
and auto-antibodies levels would lead to an immune reaction 
against nervous system components.  Moreover,  the response 
of neurological symptoms to a gluten-free diet (GFD) remains 
controversial. From this point of view, if neurological  symp-  
toms   are   independent   of   GFD,   the   presence   of   a genetic 
background facilitating the onset of multiple autoimmune 
diseases (including neurological autoimmune disorders) with 
CD may represent a co-factor.[5] 
The presence of anti-ganglioside antibodies in the serum  
of CD patients may explain neurological symptoms in CD, as 
recently supposed by different researchers; in fact, IgG anti- 
bodies against gangliosides have been found in the sera of 
adult CD patients with PN.[6] 
Gangliosides are glycosphingolipids (GM1,  GM2,  GM3,  
GD1a, GD1b, GD3, GT1a, GT1b,  GQ1b)  which  contain  sialic  
acid and are present in large amounts in the nervous system, 
especially in myelin. They can be antigenic  targets  in  a  var-  
iety of autoimmune neuropathies. The identification of anti- 
ganglioside antibodies in  large  cohorts  of  patients  with  a  
wide range of acute and chronic peripheral neuropathies and 
their association  with  particular  clinical  phenotypes  have  
been reported.[7] The possible involvement of anti-sulfatide 
antibodies in CD remains unknown. Sulfatide is a common 
glycolipid in the peripheral nerve myelin and  dorsal root gan-  
glia [8] and may be targeted by IgM  auto-antibodies  associ-  
ated with the onset of sensory axonal neuropathy or 
predominantly  demyelinating  sensorimotor  neuropathy.[9] 
Others authors confirmed the presence of anti-ganglioside 
IgG antibodies in CD patients but did not find any correlation 
 
 
 
with neurological symptoms, suggesting that anti-ganglioside 
antibodies are an epiphenomenon due to some abnormal 
antigenic presentation during an inflammatory process.[10] 
Tursi et al. [11] demonstrated that the majority of neuro- 
logical symptoms remain unmodified after GFD. Other 
researchers found that about 50% of the CD patients with 
neurological symptoms, resulting positive for at least one of 
the anti-ganglioside IgM or IgG antibodies, shows an anti- 
body disappearance after 1 year on GFD.[12] 
The present scenario appears conflicting and contradictory 
and nothing is known about the possible presence of anti- 
ganglioside and anti-sulfatide IgA antibodies, theoretically 
produced by the inflamed duodenal mucosa. 
The aim of our study was to explore a possible signifi- 
cance of the presence of anti-ganglioside and anti-sulfatide 
immunoglobulins in the sera of CD  patients. 
 
Methods 
Protocol and participants 
The sera of CD patients attending the Center for the preven-   
tion and  diagnosis  of  CD  at  the  Fondazione  IRCCS  Ca’  
Granda Ospedale Maggiore Policlinico were collected  before  
and after at least 6 months on a strict gluten-free dietary 
regimen. CD diagnosis was based upon the presence of anti- 
transglutaminase type II antibodies and duodenal atrophy 
(Marsh 3).[13] Only the sera of patients showing the normal- 
ization of anti-transglutaminase and anti-gliadin antibodies 
during GFD were analyzed. The sera of healthy blood donors 
(HBD) were also analyzed as non-CD controls. The CD clinical 
characteristics (classical CD, non-classical) were defined fol- 
lowing the Oslo definitions.[14] Any  neurological  disorders  
were  defined  based  on  clinical  neurological  examinations   
and instrumental investigations, such as electrophysiological 
testing  and  encephalic  magnetic  resonance  imaging.  The 
study was approved by the local ethics committee of the 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milano  (protocol  no. 850). 
 
Anti-ganglioside and anti-sulfatide IgG, IgM and 
IgA dosage 
The presence of anti-gangliosides (GM1, GM2, GM3, GD1a, 
GD1b, GD3, GT1a, GT1b, GQ1b) in the sera of CD patients, 
before and after GFD, and non-CD controls was detected by 
means    of    the    dot    blot    technique    (DOTZENVR ,    Zentech, 
Angleur, Belgium). The manufacturer’s instructions were fol- 
lowed. Briefly, the sera were incubated for 2 h at 4 oC on a 
rocking shaker, washed three times and further  incubated 
with peroxidase-conjugated  anti-human  immunoglobulins  
and a substrate solution revealing the presence of IgG, IgM     
or IgA auto-antibodies. The presence of blue-colored  spots 
with various intensity was considered positive. 
Peroxidase-conjugated  anti-human  IgA  was   produced  
ex novo from Zentech. Goat anti-human IgA-HRP was diluted 
into a phosphate buffer containing NaCl and calf  serum. 
The sera positive at dot blot analysis underwent a con- 
firmatory     analysis     dosage     by     means     of enzyme-linked 
immunosorbent assay (ELISA), following a previously reported 
procedure.[9] This method is  used  in  the  routine  diagnostic  
for anti-ganglioside  antibodies,  according  to  the  criteria  of  
the Italian Association of  Neuro-Immunology  (AINI)  of  
2004.[15] 
The presence of anti-sulfatide IgM, IgG and IgA auto-anti- 
bodies in the sera of CD patients, before and after GFD, and non-
CD  controls  was  also  detected  by ELISA. 
Gangliosides (Hytest, Turku, Finland) and sulfatide (Sigma 
Aldrich, St. Louis, MO) were added in ethanol to each well of 
microplate (NUNC-ImmunoTM Plates, Polysorb U96, VWR, 
Radnor, Pennsylvania) until complete evaporation at 4 oC. 
After the saturation of un-reactive sites with a blocking solu- 
tion for 4 h, a patient’s serum was added in duplicate to the 
wells and incubated overnight. After five washes, IgM, IgG or 
IgA binding was detected with peroxidase-conjugated rabbit 
anti-human IgM, IgG and IgA, respectively (Dako, Glonstrup, 
Denmark), diluted 1:500 in a blocking solution, for 2 h. After 
five washes, the color reaction was developed for 1 h before 
adding 0.1 M H2SO4 and absorbance measured  at 492 nm. 
The sera were considered positive when the difference of the 
optical density (OD) between glycolipids-coated wells and 
BSA-coated wells exceeded 0.05 OD units, in both duplicate 
wells. Positive sera were titrated by a serial two-fold dilution 
until negative. 
No anti-sulfatide reactivity IgG and  IgA  was  found  in non- 
CD controls at a dilution of 1:16,000  and  this  dilution  was  
used to analyze the sera of  the  patients  recruited  in  our  
study. The samples were considered to be positive for anti- 
sulfatide IgG and IgA antibodies when titers were equal or 
greater  than 1:16,000. 
 
Standardization ELISA 
Enzyme immunoassay with highly purified gangliosides is 
commonly used from different services for the routine diag- 
nostic of the anti-gangliosides antibodies in sera of patients 
affected by dysimmune neuropathies, according  to  the  crite- 
ria of the Italian Association of Neuro-Immunology (AINI) of 
2004.[15] 
Anti-ganglioside and sulfatides IgM antibodies are ana- 
lyzed in the serum of patients with chronic dysimmune neu- 
ropathies while anti-ganglioside IgG antibodies for acute 
clinical phenotype. 
All serum samples are added in duplicate to the initial  
dilution of 1:640, while for anti-sulfatide  antibodies  a dilution  
of 1:8000 is used. Controls of positive sera of all tested gan- 
gliosides are included in each experiment  to  ensure  validity  
and  reproducibility. 
 
Statistical analysis 
All the assumptions were verified by software, i.e., GraphPad 
Prism version 5.0 (GraphPad Software, La Jolla, CA), and a  p 
value <0.05 two tails was considered as statistically  signifi-  
cant. Kolmogorov–Smirnov’s test was used to assess the nor- 
mal distribution of the data. Continuous  variables  were 
analyzed     by     the     ANOVA     one-way     variance     test. The 
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Table 1.  Demographic characteristics of the studied cohort. 
  CD  N ¼ 22 Non-CD  N ¼ 20 p  
Gender 
Female, n (%) 17 (78) 15 (75) NS 
Male, n (%) 5 (23) 5 (25) 
Age at diagnosis (years) 40 (27–64) 39 (26–65)* NS 
GFD duration (months) 21 NA 
Type  of presentation 
Classical CD 11 (50) NA 
Non classical CD 11 (50) 
*Non-CD controls were matched with CD  patients  according  to  age  at 
diagnosis. 
CD: celiac disease; NA: not applicable; NS: not significant. 
Table 3. Patients included in the study and their auto-antibodies status before 
and after gluten-free diet.  
  CD patients (n ¼ 22)  
 
 
Type of auto-antibody 
Number of positive 
patients during 
gluten-containing diet 
Number of positive 
patients during 
gluten-free diet 
IgG anti-sulfatide 8 0 
IgG  anti-ganglio side 0 0 
IgA  anti-sulfatide 3 2 
IgA  anti-ganglio side 0 0 
IgM anti-sulfatide 0 1 
IgM anti-ganglioside 0 2 
 
Table 2.  Characteristics of patients with neurological symptoms. 
 
Neurological 
Auto-antibodies profile  
State after 
Patient symptoms Gluten þ Gluten - GFD  
 
1 Headache Anti-sulfatide IgG – U 
2 Epilepsy – – I 
3 Epilepsy  and PN – – I 
4 Epilepsy Anti-sulfatide IgG – I 
5 Headache – Anti-sulfatide  IgA    U 
6 Headache – I 
GFD:    gluten-free    diet;    I:    improvement;    PN:    peripheral    neuropathy;   
U: unchanged. 
 
significance level was further verified by multiple-comparison 
analysis with Tukey’s test. Categorical variables were com-  
pared by v2 (chi square) or Fisher’s exact tests. 
 
 
Results 
Twenty-two adult CD patients and twenty  healthy  subjects  
were enrolled (Table 1). The 11 (50%) patients with a non- 
classical CD picture, presented: iron  deficiency  anemia  7  
(64%),   hypertransaminasemia   2   (18%),   osteoporosis   1 (9%), 
recurrent abortions 2 (18%) and neurological symptoms 3 
(27%). In particular, 6 patients reported neurological symp- 
toms, 3 in a clinical picture compatible with a classical CD   
and 3 with a non-classical CD (4 females), mean age at diag- 
nosis 38 (range 33–43) and mean GFD duration 36 months 
(range 12–84). Among them, four patients reported an 
improvement after a strict GFD (Table 2). 
The auto-antibody profile of the enrolled CD patients 
before and after GFD is reported in Table 3. On a gluten-con- 
taining diet, anti-sulfatide IgA antibodies were present in 3 
(19%) patients and only in one case their persistence was 
observed after a strict GFD. Moreover, anti-sulfatide IgA anti- 
bodies appeared in one case during GFD; no anti-sulfatide   
IgA positivity was observed in all 6 patients having neuro- 
logical symptoms on a gluten-containing diet (Table  2). 
Anti-sulfatide,  anti-GM1  and  anti-GM2  IgM  antibodies  
were also observed in 2 treated patients. All the other auto- 
antibodies were absent and no demographic or clinical 
parameters were  associated with their   positivity. 
On a gluten-containing diet, anti-sulfatide IgG antibodies 
were observed in 8 (36%) patients of our study.  Among  
them, 2 patients presented neurological disorders (headache, 
epilepsy) with no statistical difference between the group of 
patients   with   and   without   neurological   disorders.   Anti- 
 
 
Figure  1.  Anti-sulfatide IgG,  IgA, IgM reactivity in celiac patients before and  
after gluten-free diet. GFD: gluten-free diet; NS: not significant. 
 
sulfatide IgG antibodies disappeared in all the patients dur- 
ing a GFD (Figure  1). 
In general, 12 (59%) CD patients presented at least one of 
the tested auto-antibodies vs. none of the non-CD controls 
presented them (p < 0.0001). While on a gluten-containing 
diet, 10 (45%) of CD patients presented at least one of the 
tested auto-antibodies vs. 4 (18%) during GFD (p ¼ 0.02). 
 
Discussion 
For the first time in CD, we found the presence of  anti-sulfa-  
tide IgG and IgA auto-antibodies. Anti-sulfatide IgG disap-  
peared during GFD,  while  IgA  were  independent  of  the  
gluten  withdrawal  (Figure 1). 
The binding site and the fine specificity of the anti-sulfa- 
tide antibodies may determine a particular clinical neuro- 
pathic syndrome. The presence of anti-sulfatide IgG and IgA 
antibodies was reported in patients with neurological disor- 
ders. The anti-sulfatide IgG antibodies were initially found in 
patients  with  acute  immune-mediated  polyradiculoneurop- 
athy,  the  Guillain–Barr,e  Syndrome  (GBS)  while  anti-sulfatide 
and anti-ganglioside IgA antibodies in patients affected by 
GBS, after Campylobacter jejuni  enteritis.[16–19] 
The gangliosides in peripheral nerves were subsequently 
targeted by serum antibodies in patients with GBS and inter- 
action between anti-ganglioside IgG antibodies and periph- 
eral nerve ganglioside is believed to cause GBS and its 
variants.[20] 
More recently, high titers of  anti-sulfatide  antibodies,  
mostly IgM, have been associated with inflammatory demye- 
linating  neuropathies  [21]  and  subsequently  with  a  chronic 
  
mostly sensorimotor dysimmune neuropathy [16,9] and small-
fiber neuropathy.[22,23] 
Alaedini et al. [6] detected the presence of IgG antibodies 
against at least one or more gangliosides  (GM1,  GM2,  GD1a 
and GD1b) in 6 adult CD patients with distal sensory neur- 
opathy, suggesting a T-cell mediated autoimmune response 
against gangliosides. Volta et al. [12] found a positivity to at  
least one of the three anti-ganglioside IgG antibodies (GM1, 
GD1b and GQ1b) in 64% of CD patients with a neurological 
dysfunction and in 30% of CD patients without neurological 
symptoms. Although the limited number  of  patients  pre- 
cludes a definitive statement, no association has been found 
between the analyzed auto-antibodies and the neurological 
symptoms  included  headache,[24]  as  recently  described  in  
CD  in  our study. 
Anti-ganglioside IgA antibodies have been reported  for  
the first time in patients affected by GBS.[18] In particular, 
anti-ganglioside GM1 IgA antibodies have been detected in 
patients with GBS after Campylobacter jejuni enteritis,[19] 
suggesting a possible link between intestinal inflammation, 
IgA production and autoimmune neuropathies. An auto- 
immune response to GM1 could be determined by molecu- 
lar mimicry and a successive T-cell mediated pathway, 
responsible for the clinical manifestations. However, in line 
with our findings, no association has  been  reported  
between IgA and clinical phenotypes. In our study, the 
absence of anti-ganglioside and anti-sulfatide IgA antibodies 
in CD patients with neurological symptoms on a gluten-con- 
taining diet may suggest a different mechanism while the 
presence of anti-sulfatide IgA antibodies during GFD may 
indicate higher susceptibility to develop an autoimmune 
response independently of gluten. 
Anti-sulfatide,  anti-GM1  and  anti-GM2  IgM  antibodies  
were also observed in 2 treated CD patients without neuro- 
logical disorders. Both patients did not show other auto-  
immune diseases and no neurological disorder associated to 
these auto-antibodies, such as sensory demyelinating poly- 
neuropathy  and  multifocal  motor neuropathy.[9,25] 
Gangliosides are highly expressed on intestinal  epithelial  
cells  [26]  and  anti-ganglioside  antibodies  have  been 
described in CD with neurological symptoms.[6,10–12] The 
binding of gliadin to ganglioside on the intestinal epithelium 
might have a role in the anti-gliadin immune response and 
contribute to the intestinal inflammatory reaction in CD.[27] 
The presence of IgG auto-antibodies in our patients with 
and without neurological symptoms on a gluten-containing 
diet and their total absence in non-CD controls suggests a 
possible connection between auto-antibodies and the enter- 
opathy through a similar mechanism. Their disappearance in 
all the patients may be suggestive of a possible link between 
gluten and IgG auto-antibodies. 
Anti-sulfatide IgG reactivity in patients with non-classical 
CD and neurological symptoms may indicate an acute phase 
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